[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643880":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":51,"collaborators":24,"id":55,"slug":24,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":24,"eligibilityCriteria":59,"healthyVolunteers":56,"sex":60,"minAge":61,"maxAge":24,"enrollmentInfo":62,"targetDuration":24,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":24,"overallStatus":36,"whyStopped":24,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group HA","EXPERIMENTAL","Patients will be given intra-articular injection of 2 ml of hyaluronic acid into the joint space three times weekly.",[13],"Drug: Hyaluronic acid",{"label":15,"type":10,"description":16,"interventionNames":17},"Group BTX","Patients will be given intra-articular injection of 100 units of Botulinum toxin type A, diluted with 5 ml of normal saline three times weekly.",[18],"Drug: Botulinum toxin type A",[20,25],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG","Hyaluronic acid",[9],null,{"type":21,"name":26,"description":16,"armGroupLabels":27,"otherNames":24},"Botulinum toxin type A",[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":24,"email":33},"Mohammed S ElSharkawy, MD","CONTACT","00201148207870","mselsharkawy@med.tanta.edu.eg",[35],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Tanta","El-Gharbia","31527","Egypt","EG",{"type":43,"coordinates":44},"Point",[45,46],31.00192,30.78847,{"lat":46,"lon":45},[49],{"name":50,"role":31,"phone":32,"phoneExt":24,"email":33},"Mohammed S Elsharkawy, MD",{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Mohammed Said ElSharkawy","Lect urer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.","100643880",false,"NCT07666347","Intraarticular Injection of Botox and Hyaluronic Acid in Knee Osteoarthritis","Inclusion Criteria:\n\n* Age ≥ 50 years.\n* Both genders.\n* Chronic knee osteoarthritis (KOA) according to American College of Rheumatology criteria for the diagnosis of knee osteoarthritis.\n* Third or fourth grade Kellgren and Lawrence system for classification of osteoarthritis based on radiological data, it is a common method of classifying the severity of osteoarthritis (OA) using five grades according to the following sites and projections.\n\nExclusion Criteria:\n\n* History of intra-articular injection within the last 6 months,\n* History of surgery on the knee joint or major trauma to the lower limb causing fracture.\n* Body mass index (BMI) more than 40 kg\u002Fm2.\n* Medical conditions affecting the joint or lower extremity function such as severe osteoporosis, rheumatoid arthritis, collagen vascular diseases, and gout.\n* Diabetic patient.\n* Any contraindication to intra-articular injections for instance immunodeficiency, coagulation defect or anticoagulation therapy taking or skin infection at the site of injection.\n* Hypersensitivity to Botulinum toxin or hyaluronic acid.","ALL","50 Years",{"count":63,"type":64},50,"ESTIMATED","INTERVENTIONAL",[67],"NA","This study aims to compare the efficacy of intra-articular injection of Botulinum toxin and hyaluronic acid on pain in knee osteoarthritis.",[70,71,72,73],"Intraarticular Injection","Botox","Hyaluronic Acid","Knee Osteoarthritis","2026-06-24",{"date":76,"type":77},"2026-06-25","ACTUAL",{"date":74,"type":77},{"date":80,"type":64},"2026-12-01",{"name":5,"class":6},1]